๐๐ก๐ฉ๐-๐๐-๐๐๐ฅ๐๐๐ ๐ช๐๐๐๐๐ฌ ๐๐๐๐ง๐๐ข๐ก - ๐ฎ๐ณ ๐๐ป๐ฑ๐ถ๐ฎ ๐๐ฎ๐๐ป๐ฐ๐ต๐ฒ๐ ๐๐๐ฃ๐ ๐๐ฎ๐ป๐ฑ๐ฏ๐ผ๐ผ๐ธ ๐๐ผ ๐๐ป๐ฎ๐ฏ๐น๐ฒ ๐ง๐ฟ๐๐๐๐ฒ๐ฑ ๐๐ฎ๐๐ฎ ๐ฆ๐ต๐ฎ๐ฟ๐ถ๐ป๐ด ๐ณ๐ผ๐ฟ ๐๐ ๐ง๐ฟ๐ฎ๐ถ๐ป๐ถ๐ป๐ด
๐๐ก๐ฉ๐-๐๐-๐๐๐ฅ๐๐๐ ๐ช๐๐๐๐๐ฌ EDITION ━━━━━━━━━━━━━━━━━━━━━━━━ ๐ฐ ๐๐ ๐ก๐๐ช๐ฆ 1. ๐งฌ ๐๐ป๐๐ต๐ฟ๐ผ๐ฝ๐ถ๐ฐ ๐ฅ๐ฒ๐๐ฒ๐ฎ๐น๐ ๐๐น๐ฎ๐๐ฑ๐ฒ'๐ ๐๐ฎ๐ฟ๐น๐ ๐ฃ๐ฟ๐ผ๐ด๐ฟ๐ฒ๐๐ ๐ถ๐ป ๐๐ฟ๐๐ด ๐๐ถ๐๐ฐ๐ผ๐๐ฒ๐ฟ๐ ๐๐ฐ๐ฟ๐ผ๐๐ ๐ฆ๐ถ๐
๐๐ถ๐ผ๐๐ฒ๐ฐ๐ต ๐ฃ๐ฎ๐ฟ๐๐ป๐ฒ๐ฟ๐๐ต๐ถ๐ฝ๐ ๐ฐ ๐ช๐๐๐ง ๐๐๐ฃ๐ฃ๐๐ก๐๐ !! Anthropic has detailed early results from collaborations with six life-sciences organisations: BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group. The work applies Claude across different stages of drug development, from antibody design and experimental optimisation to manufacturing documentation and clinical-trial planning. Anthropic also described its acquisition of Mithril Medicine, a one-person biotech whose Claude-assisted muscular-dystrophy programme produced promising results in mice. The company stresses that this work remains early and largely preclinical; none of the treatments described is an approved medicine or a pro...